caa a22 4500 465738982 CHVBK 20180323111803.0 cr unu---uuuuu 170327e19900301xx s 000 0 eng 10.1007/BF02244611 doi (NATIONALLICENCE)springer-10.1007/BF02244611 Bromazepam in generalized anxiety [Elektronische Daten] Randomized, multi-practice comparisons with both chlorprothixene and placebo [P. Kragh-Sørensen, P. Holm, C. Fynboe, E. Schaumburg, B. Andersen, P. Bech, J. Pichard] Bromazepam was compared with placebo and with chlorprothixene in a randomized, double-blind group-comparative multicenter trial in general practice. Two hundred and forty-five patients with generalized anxiety disorder (DSM-III 1980) were treated for 2 weeks with two daily doses of bromazepam, 3 mg or chlorprothixene, 15 mg or placebo. Median reductions in Hamilton Anxiety rating were 12 (bromazepam), 10.3 (chlorprothixene) and 7.3 (placebo). The study revealed significant superiority of bromazepam over placebo (median differences 3.3, 95% confidence limits: 0.3 and 6.1) but not over chlorprothixene (median difference 1.4, 95% confidence limits −0.8 and +3.5). Significantly higher rates of tiredness, sedation and hypersomnia were found on bromazepam and chlorprothixene compared to placebo. Tolerance was rated as "at least good” in 85.6% on bromazepam, in 86% on chlorprothixene and in 87.8% on placebo. Neither previous psychopharmacological treatment nor presence of psychosocial stress were of perceptible influence. Bromazepam and chlorprothixene are both superior to placebo in generalized anxiety states treated in general practice, but spontaneous improvements/placebo effects are substantial. Springer-Verlag, 1990 Benzodiazepine nationallicence Neuroleptic nationallicence Placebo nationallicence Generalized anxiety nationallicence Randomized trial nationallicence General practice nationallicence Kragh-Sørensen P. Department of Psychiatry, Odense University Hospital, DK-5000, Odense C, Denmark aut Holm P. International Clinical Research (Nordic Region) Roche A/S, Copenhagen aut Fynboe C. aut Schaumburg E. aut Andersen B. Department D of Surgical Gastroenterology, Herlev University Hospital, Denmark aut Bech P. Department of Psychiatry P, General Hospital, Hillerød, Denmark aut Pichard J. International Clinical Research (Nordic Region) Roche A/S, Copenhagen aut Psychopharmacology Springer-Verlag 100/3(1990-03-01), 383-386 0033-3158 100:3<383 1990 100 213 https://doi.org/10.1007/BF02244611 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF02244611 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Kragh-Sørensen P. Department of Psychiatry, Odense University Hospital, DK-5000, Odense C, Denmark aut NATIONALLICENCE 700 1- Holm P. International Clinical Research (Nordic Region) Roche A/S, Copenhagen aut NATIONALLICENCE 700 1- Fynboe C. aut NATIONALLICENCE 700 1- Schaumburg E. aut NATIONALLICENCE 700 1- Andersen B. Department D of Surgical Gastroenterology, Herlev University Hospital, Denmark aut NATIONALLICENCE 700 1- Bech P. Department of Psychiatry P, General Hospital, Hillerød, Denmark aut NATIONALLICENCE 700 1- Pichard J. International Clinical Research (Nordic Region) Roche A/S, Copenhagen aut NATIONALLICENCE 773 0- Psychopharmacology Springer-Verlag 100/3(1990-03-01), 383-386 0033-3158 100:3<383 1990 100 213 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer